Meeting
2011 ASCO Annual Meeting
A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
Authors
F. Saad
University of Montreal Hospital Center, Montreal, QC, Canada
F. Saad , H. Akaza , M. A. Eisenberger , J. Nelson , H. I. Scher , K. Suzuki , M. Wirth , I. J. Webb , J. Wang , D. MacLean , R. De Wit
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01193244
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS184)
Abstract #
TPS184
Poster Bd #
46F
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).
First Author: Robert Dreicer
Poster
2011 ASCO Annual Meeting
Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
First Author: D. B. Agus
Poster
2014 Genitourinary Cancers Symposium
Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.
First Author: Evan Y. Yu
Poster
2017 ASCO Annual Meeting
Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Evan Y. Yu